Inhibikase Therapeutics, Inc.(IKT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

IKT Inhibikase Therapeutics, Inc.

Trading 04-10 12:01:46 EDT

1.79

-0.10

-5.29%

High1.87	Low1.73	Vol10.92K
Open1.87	D1 Closing1.89	Amplitude7.41%
Mkt Cap133.07M	Tradable Cap30.79M	Total Shares74.34M
T/O19.68K	T/O Rate0.06%	Tradable Shares17.20M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"IKT","market":"US","secType":"STK","nameCN":"Inhibikase Therapeutics, Inc.","latestPrice":1.79,"timestamp":1744300897314,"preClose":1.89,"halted":0,"volume":10917,"delay":0,"floatShares":17201336,"shares":74341540,"eps":-1.160578,"marketStatus":"Trading","change":-0.1,"latestTime":"04-10 12:01:44 EDT","open":1.87,"high":1.87,"low":1.73,"amount":19683.8193393,"amplitude":0.074074,"askPrice":1.8,"askSize":700,"bidPrice":1.78,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.160578,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1744315200000},"marketStatusCode":2,"adr":0,"listingDate":1608699600000,"exchange":"NASDAQ","adjPreClose":1.89,"preHourTrading":{"tag":"盘前","latestPrice":1.9,"preClose":1.89,"latestTime":"09:21 EDT","volume":3,"amount":5.699999999999999,"timestamp":1744291306177},"postHourTrading":{"tag":"盘后","latestPrice":1.89,"preClose":1.89,"latestTime":"18:19 EDT","volume":505,"amount":954.5488,"timestamp":1744237163301},"volumeRatio":0.156667},"requestUrl":"/m/hq/s/IKT/wiki","defaultTab":"wiki","newsList":[{"id":"2524128200","title":"Hedge funds owners may consider drastic measures as Inhibikase Therapeutics, Inc.'s (NASDAQ:IKT) recent US$29m drop adds to long-term losses","url":"https://stock-news.laohu8.com/highlight/detail?id=2524128200","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524128200?lang=en_us&edition=full_marsco","pubTime":"2025-04-04 21:13","pubTimestamp":1743772396,"startTime":"0","endTime":"0","summary":"Institutions' substantial holdings in Inhibikase Therapeutics implies that they have significant influence over the company's share price. 55% of the business is held by the top 6 shareholders. Ownership research along with  analyst forecasts data  help provide a good understanding of opportunities in a stock. Trump has pledged to \"unleash\" American oil and gas and these 15 US stocks have developments that are poised to benefit.Our data indicates that hedge funds own 31% of Inhibikase Therapeutics. That catches my attention because hedge funds sometimes try to influence management, or bring about changes that will create near term value for shareholders. Looking at our data, we can see that the largest shareholder is Sands Capital Ventures, LLC with 15% of shares outstanding. With 8.5% and 8.2% of the shares outstanding respectively, Soleus Capital Management, L.P. and Fairmount Funds Management LLC are the second and third largest shareholders.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/hedge-funds-owners-may-consider-131316926.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B64PRP62.GBP",".IXIC","LU2210149790.SGD","LU2095319765.USD","IE00B3QW5Z07.USD","NVIW.SI","TQQQ","QID","TSYW.SI","IE00BGHQF748.EUR","IKT","SQQQ","NDAQ","BK4585","PSQ","MNQmain","NQmain","BK4588","USAW.SI","LU2210150020.SGD","QLD","BK4112","BK4139","USJW.SI","IE00BKPKM429.USD"],"gpt_icon":1},{"id":"2522326555","title":"Inhibikase Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2522326555","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522326555?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 04:56","pubTimestamp":1743109018,"startTime":"0","endTime":"0","summary":"Inhibikase Therapeutics Inc reports results for the quarter ended December 31 - Earnings SummaryInhibikase Therapeutics Inc IKT.OQ reported a quarterly adjusted loss of 50 cents per share for the quar","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nL5N3QA252:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IKT"],"gpt_icon":0},{"id":"2522539552","title":"Inhibikase Therapeutics FY 2024 GAAP EPS $(1.16) Misses $(0.90) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2522539552","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522539552?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 04:03","pubTimestamp":1743105823,"startTime":"0","endTime":"0","summary":"Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(1.16) per share which missed the analyst consensus estimate of $(0.90) by 28.89 percent. This is a 63.29 percent increase over losses of $(3.16) per","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44523592/inhibikase-therapeutics-fy-2024-gaap-eps-1-16-misses-0-90-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","IKT"],"gpt_icon":0},{"id":"2522539328","title":"Press Release: Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity","url":"https://stock-news.laohu8.com/highlight/detail?id=2522539328","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522539328?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 04:01","pubTimestamp":1743105660,"startTime":"0","endTime":"0","summary":"New Leadership and Focus on Advancement of IkT-001 into a Late-Stage Clinical Trial Program in Pulmonary Arterial Hypertension. BOSTON, March 27, 2025  -- Inhibikase Therapeutics, Inc.  , a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor therapeutics to treat pulmonary arterial hypertension , today reported financial results for the year ended December 31, 2024 and highlighted recent developments.\"The financing concluded in October positioned us to focus our clinical development efforts on advancing IkT-001 toward a late-stage clinical trial in PAH,\" said Mark Iwicki, Chief Executive Officer of Inhibikase. \"To drive the Company toward its next phase of growth, we subsequently added depth to our management team with the additions of Chris Cabell and John Adams, two accomplished scientific leaders with established track records in the PAH space. Additionally, we expect Chris and John will enable us to accelerate the build out of our team as we make prepar","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","IKT","BK4139","NQmain"],"gpt_icon":0},{"id":"2522329609","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2522329609","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522329609?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 18:00","pubTimestamp":1743069600,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·INmune Bio Inc.                                 4Q      (.55)  4:05 PM. ·TD SYNNEX Corp                                   1Q      2.91   8:05 AM","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BW","NNOX","PVH","BRZE","BHST","CELC","LNZA","SKYH","GOVX","PENG","FC","CRDL","SDST","FBIO","EDAP","ADCT","BLRX","UNCY","TSAT","INR","IKT","INMB","PVLA","SGML","BCAB","REKR","NUTX","GWH","PRGS","ANGO","DARE","MDAI","WGO","LULU","ATAI","CLSD","NCNO","WBA","CALC","RANI","WKSP","SPWH","GEVO","RLMD","SLRN","TLSI","KYTX","FTCI","FEMY","AFMD"],"gpt_icon":0},{"id":"2521714099","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2521714099","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521714099?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 18:00","pubTimestamp":1742810400,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Comp de San Bas                                  4Q       .36       AMC. ·Oklo Inc. Class A                               4Q      (.07)      AMC. ·Core & Main Inc.                                 4Q       .36       BMO. ·McCormick & Co                                 1Q       .64   6:30 AM","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTAS","TEN","DERM","ABL","PDSB","MLKN","GOVX","SCS","CRMD","SDST","FBIO","EDAP","BEEM","ZURA","UNCY","KBH","ALUR","ANTX","THRD","IKT","OBIO","BCAB","ACRV","GRDN","DLTR","LPTX","NUTX","SKYX","RVPH","IOBT","MDAI","WGO","CDLR","CHWY","CLSD","MREO","WBA","CALC","WOOF","RLMD","CNXC","MKC","IVA","PAYX","SLRN","KOD","SURG","XFOR","PAYS","AFMD"],"gpt_icon":0},{"id":"2521851462","title":"Inhibikase Therapeutics Inc  expected to post a loss of 9 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2521851462","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521851462?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 20:28","pubTimestamp":1742560086,"startTime":"0","endTime":"0","summary":"Inhibikase Therapeutics Inc  expected to post a loss of9cents a share - Earnings Preview Inhibikase Therapeutics Inc IKT.OQ IKT.O is expected to show no change in quarterly revenue when it reports  re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250321:nL8N3Q410G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IKT"],"gpt_icon":0},{"id":"2517447769","title":"Inhibikase Therapeutics (IKT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2517447769","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517447769?lang=en_us&edition=full_marsco","pubTime":"2025-03-05 22:55","pubTimestamp":1741186505,"startTime":"0","endTime":"0","summary":"A downtrend has been apparent in Inhibikase Therapeutics, Inc.  lately. While the stock has lost 15.4% over the past two weeks, it could witness a trend reversal as a hammer chart pattern was formed in its last trading session. This could mean that the bulls have been able to counteract the bears to help the stock find support.While the formation of a hammer pattern is a technical indication of nearing a bottom with potential exhaustion of selling pressure, rising optimism among Wall Street analysts about the future earnings of this company is a solid fundamental factor that enhances the prospects of a trend reversal for the stock.What is a Hammer Chart and How to Trade It?If this is not enough, you should note that IKT currently has a Zacks Rank #2 , which means it is in the top 20% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises. And stocks carrying a Zacks Rank #1 or 2 usually outperform the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/inhibikase-therapeutics-ikt-may-bottom-145505815.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IKT","BK4139"],"gpt_icon":0},{"id":"2513725022","title":"Inhibikase Announces Expansion of Senior Leadership Team","url":"https://stock-news.laohu8.com/highlight/detail?id=2513725022","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513725022?lang=en_us&edition=full_marsco","pubTime":"2025-02-24 21:00","pubTimestamp":1740402001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nTUA7K8NGB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IKT","BK4139"],"gpt_icon":0},{"id":"2513263307","title":"Inhibikase Announces Expansion of Senior Leadership Team","url":"https://stock-news.laohu8.com/highlight/detail?id=2513263307","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513263307?lang=en_us&edition=full_marsco","pubTime":"2025-02-24 21:00","pubTimestamp":1740402000,"startTime":"0","endTime":"0","summary":"--- Chris Cabell, MD MHS FACC Appointed President and Head of Research & Development ---. --- John Adams, PhD Appointed Chief Scientific Officer ---. “I know Chris and John well from our time at Arena,” said Amit Munshi, Chairman of the Board of Directors of Inhibikase. “Their clinical trial efforts on PAH medicine, ralinepag, proved critical to the successful licensing of that asset to United Therapeutics. I am also delighted to welcome Vince to our Board of Directors. Vince’s extensive experience in corporate strategy and business development will be an important asset for the Company moving forward.”Chris Cabell, MD MHS FACC., – Dr. Cabell is a cardiologist and joins Inhibikase from CorHepta, where he was Chief Executive Officer. Previously, Dr. Cabell was Chief Medical Officer at Arena Pharmaceuticals, Zura Bio, and Emergent Bio Solutions. Dr. Cabell has also served on multiple corporate and scientific advisory boards. Earlier in his career Dr. Cabell was","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/inhibikase-announces-expansion-senior-leadership-130000903.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TISI","IKT","BK4120"],"gpt_icon":0},{"id":"2512196154","title":"Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company’s Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2512196154","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512196154?lang=en_us&edition=full_marsco","pubTime":"2025-02-18 21:00","pubTimestamp":1739883600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250218:nTUAKJ2TK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IKT"],"gpt_icon":0},{"id":"2510379891","title":"HC Wainwright Downgrades Inhibikase Therapeutics to Neutral From Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2510379891","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510379891?lang=en_us&edition=full_marsco","pubTime":"2025-02-12 20:58","pubTimestamp":1739365123,"startTime":"0","endTime":"0","summary":"Inhibikase Therapeutics (IKT) has an average rating of overweight and mean price target of $7, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IKT","LENZ"],"gpt_icon":0},{"id":"2510322323","title":"Inhibikase Therapeutics, Inc. : H.c. Wainwright Cuts to Neutral From Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2510322323","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510322323?lang=en_us&edition=full_marsco","pubTime":"2025-02-12 19:04","pubTimestamp":1739358246,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250212:nAZN3CKT2Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IKT","BK4139"],"gpt_icon":0},{"id":"2507969780","title":"Insiders Enjoy US$1.1m Return After Buying Inhibikase Therapeutics Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2507969780","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507969780?lang=en_us&edition=full_marsco","pubTime":"2025-01-31 18:52","pubTimestamp":1738320741,"startTime":"0","endTime":"0","summary":"Insiders who purchased Inhibikase Therapeutics, Inc. ( NASDAQ:IKT ) shares in the past 12 months are unlikely to be...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ikt/inhibikase-therapeutics/news/insiders-enjoy-us11m-return-after-buying-inhibikase-therapeu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LENZ","BK4139","IKT"],"gpt_icon":0},{"id":"2507620386","title":"Inhibikase Therapeutics stops Parkinson's drug development as it fails to show benefits in study","url":"https://stock-news.laohu8.com/highlight/detail?id=2507620386","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507620386?lang=en_us&edition=full_marsco","pubTime":"2025-01-30 07:29","pubTimestamp":1738193340,"startTime":"0","endTime":"0","summary":"Jan 29  - Inhibikase Therapeutics IKT.O said on Wednesday it would stop development of its experimental Parkinson's disease drug after it failed to improve patients' ability to carry out daily tasks such as eating and walking in a mid-stage study.Shares of the drug developer tumbled nearly 22% to $2.19 in extended trading. However, the drug, risvodetinib, was found to be safe and well tolerated, meeting the main goal of the study, the company said.The study enrolled 126 people with untreated Parkinson's disease, a progressive neurological disorder that impairs the brain's nerve cells and affects the production of dopamine, a neurotransmitter that regulates functions such as memory, movement and mood.It is estimated that 1 million people in the U.S. live with the incurable condition.The established standard of care for the disease, levodopa, acts as a replacement agent for dopamine.Last month, AbbVie's ABBV.N experimental drug, tavapadon, helped significantly improve patients' ability t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250129:nL3N3OP1WT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0965509101.SGD","LU0211327993.USD","LU0689472784.USD","BK4550","LU0203345920.USD","IE00B3PB1722.GBP","LU1551013425.SGD","LU1934455277.USD","LU1267930490.SGD","LU2237443978.SGD","LU0211328371.USD","IKT","LU0943347566.SGD","LU2347655156.SGD","LU1003077747.HKD","LU0310800379.SGD","LU0820561909.HKD","LU1057294990.SGD","LU2237443549.SGD","LU0234570918.USD","SG9999001440.SGD","LU0456855351.SGD","ABBV","LU0795875169.SGD","LU1093756168.USD","LU1244550577.SGD","LU2023251221.USD","IE00BGHQF631.EUR","IE00BSNM7G36.USD","LU0965508806.USD","LU0882574055.USD","LU1267930573.SGD","LU2089284900.SGD","LU1037948541.HKD","BK4533","LU0795875086.SGD","SG9999015978.USD","LU0738911758.USD","LU2237443465.HKD","BK4588","SG9999011175.SGD","SG9999015952.SGD","LU0029864427.USD","LU1585245621.USD","IE0009355771.USD","LU0234572021.USD","LU1551013342.USD","SG9999015986.USD","IE0004445239.USD","LU0965509010.AUD"],"gpt_icon":0},{"id":"2507624026","title":"BRIEF-Inhibikase Therapeutics Inc Says 201 Trial Met Primary Endpoint Of Safety And Tolerability","url":"https://stock-news.laohu8.com/highlight/detail?id=2507624026","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507624026?lang=en_us&edition=full_marsco","pubTime":"2025-01-30 07:25","pubTimestamp":1738193144,"startTime":"0","endTime":"0","summary":"BRIEF-Inhibikase Therapeutics Inc Says 201 Trial Met Primary Endpoint Of Safety And TolerabilityJan 29 (Reuters) - Inhibikase Therapeutics Inc IKT.O:INHIBIKASE THERAPEUTICS INC - 201 TRIAL MET PRIMARY","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250129:nFWN3OP1OK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IKT"],"gpt_icon":0},{"id":"2507669393","title":"Inhibikase Therapeutics Inc - Risvodetinib Treatment Did Not Show Improvement in Top Hierarchical Efficacy Measure","url":"https://stock-news.laohu8.com/highlight/detail?id=2507669393","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507669393?lang=en_us&edition=full_marsco","pubTime":"2025-01-30 05:58","pubTimestamp":1738187917,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250129:nFWN3OP1OK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IKT","BK4139"],"gpt_icon":0},{"id":"2507669330","title":"Inhibikase Therapeutics Inc - 201 Trial Met Primary Endpoint of Safety and Tolerability","url":"https://stock-news.laohu8.com/highlight/detail?id=2507669330","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507669330?lang=en_us&edition=full_marsco","pubTime":"2025-01-30 05:58","pubTimestamp":1738187917,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250129:nFWN3OP1OK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IKT","BK4139"],"gpt_icon":0},{"id":"2505231372","title":"Bullish Inhibikase Therapeutics Insiders Loaded Up On US$2.70m Of Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2505231372","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505231372?lang=en_us&edition=full_marsco","pubTime":"2025-01-21 19:12","pubTimestamp":1737457930,"startTime":"0","endTime":"0","summary":"Quite a few insiders have dramatically grown their holdings in Inhibikase Therapeutics, Inc.  over the past 12 months. An insider's optimism about the company's prospects is a positive sign.Although we don't think shareholders should simply follow insider transactions, we do think it is perfectly logical to keep tabs on what insiders are doing.Inhibikase Therapeutics Insider Transactions Over The Last Year. The Chairman Roberto Bellini made the biggest insider purchase in the last 12 months. That single transaction was for US$2.0m worth of shares at a price of US$1.37 each. Although we like to see insider buying, we note that this large purchase was at significantly below the recent price of US$2.72. While it does suggest insiders consider the stock undervalued at lower prices, this transaction doesn't tell us much about what they think of current prices.For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We cu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bullish-inhibikase-therapeutics-insiders-loaded-111210079.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","BK4139","IKT"],"gpt_icon":0},{"id":"2489414471","title":"Inhibikase Adjusts and Terminates Stock Offering Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2489414471","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489414471?lang=en_us&edition=full_marsco","pubTime":"2024-12-06 06:18","pubTimestamp":1733437107,"startTime":"0","endTime":"0","summary":"Inhibikase Therapeutics ( ($IKT) ) has provided an announcement. Inhibikase Therapeutics entered an At the Market Offering Agreement with H.C. Wain...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/inhibikase-adjusts-and-terminates-stock-offering-agreement?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/inhibikase-adjusts-and-terminates-stock-offering-agreement?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","IKT"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.inhibikase.com","stockEarnings":[{"period":"1week","weight":-0.133},{"period":"1month","weight":-0.0503},{"period":"3month","weight":-0.3903},{"period":"6month","weight":0.2857},{"period":"1year","weight":-0.1127},{"period":"ytd","weight":-0.4185}],"compareEarnings":[{"period":"1week","weight":-0.0282},{"period":"1month","weight":-0.0213},{"period":"3month","weight":-0.0693},{"period":"6month","weight":-0.0534},{"period":"1year","weight":0.0564},{"period":"ytd","weight":-0.0639}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a small molecule Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, University of Bordeaux, and Michigan State University, as well as University of California; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.280454},{"month":2,"riseRate":0.6,"avgChangeRate":-0.092117},{"month":3,"riseRate":0.2,"avgChangeRate":0.027077},{"month":4,"riseRate":0,"avgChangeRate":-0.201345},{"month":5,"riseRate":0.75,"avgChangeRate":0.088455},{"month":6,"riseRate":0,"avgChangeRate":-0.283409},{"month":7,"riseRate":0.5,"avgChangeRate":-0.045361},{"month":8,"riseRate":0.5,"avgChangeRate":-0.009087},{"month":9,"riseRate":0,"avgChangeRate":-0.157472},{"month":10,"riseRate":0.5,"avgChangeRate":0.119822},{"month":11,"riseRate":0.75,"avgChangeRate":0.000349},{"month":12,"riseRate":0.5,"avgChangeRate":0.007213}],"exchange":"NASDAQ","name":"Inhibikase Therapeutics, Inc.","nameEN":"Inhibikase Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.2","shortVersion":"4.32.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Inhibikase Therapeutics, Inc.(IKT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Inhibikase Therapeutics, Inc.(IKT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Inhibikase Therapeutics, Inc.,IKT,Inhibikase Therapeutics, Inc.股票,Inhibikase Therapeutics, Inc.股票老虎,Inhibikase Therapeutics, Inc.股票老虎国际,Inhibikase Therapeutics, Inc.行情,Inhibikase Therapeutics, Inc.股票行情,Inhibikase Therapeutics, Inc.股价,Inhibikase Therapeutics, Inc.股市,Inhibikase Therapeutics, Inc.股票价格,Inhibikase Therapeutics, Inc.股票交易,Inhibikase Therapeutics, Inc.股票购买,Inhibikase Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Inhibikase Therapeutics, Inc.(IKT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Inhibikase Therapeutics, Inc.(IKT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction